Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab pharmacokinetic prediction of response in ulcerative colitis
2018-001051-12Phase 4Completed
- Sponsor
- CHU Saint-Etienne
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vedolizumab in autoimmune colitis, sponsored by CHU Saint-Etienne. Primary endpoints: Week 6 vedolizumab threshold predicting week 10 clinical response, Week 14 vedolizumab threshold predicting week 52 clinical remission and 1 more. Started Apr 2018; status: completed.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2018-001051-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001051-12.